The expression of TRIM32 is upregulated in several malignancies such as gastric cancer (GC), non-small-cell lung cancer (NSCLC), and hepatocellular carcinoma (HCC) (9–11). Here, TRIM32 is linked to non-small cell lung carcinoma.